IGC Pharma Strengthens Regulatory Readiness as Phase 2 CALMA Alzheimer's Trial Approaches Enrollment Closure and Q4 Topline Readout

Rhea-AI Summary

IGC Pharma (NYSE American: IGC) reported that its Phase 2 CALMA trial of lead Alzheimer's candidate IGC-AD1 is nearing enrollment completion, with 160 participants randomized and up to eight additional randomizations expected before closure. Topline results are anticipated in the fourth quarter of 2026.

According to IGC Pharma, the company is expanding its regulatory, biostatistical, AI-enabled data science, and strategic development capabilities to support data review, AI-assisted data quality, and preparedness for potential FDA and EMA interactions, as well as evaluation by potential pharmaceutical partners after trial completion.

IGC Pharma has engaged OPIS Research, a global contract research organization, to support EMA-related regulatory activities. CALMA is a randomized, double-blind, placebo-controlled Phase 2 study in agitation associated with Alzheimer's dementia, positioned as one of the company’s key upcoming clinical milestones.

Positive

• 160 CALMA participants randomized with up to eight more expected before enrollment closure
• Phase 2 CALMA topline results expected in Q4 2026
• Expanded regulatory and AI-enabled data capabilities to support CALMA data quality and review
• Engagement of OPIS Research to support EMA-related regulatory interactions
• CALMA positioned as one of the company’s most significant upcoming clinical milestones

Negative

• None.

Market Context

The tag-specific history recorded both 10.17% and -2.09% reactions to CALMA-related updates, adding ...

Analysis

The tag-specific history recorded both 10.17% and -2.09% reactions to CALMA-related updates, adding a mixed comparator to this enrollment-readiness announcement. The resale registration concerns existing holders, and low short positioning leaves trial execution and readout timing as key watch items.

Key Figures

Randomized participants: 160 participants Additional randomizations: Up to 8 participants Trial phase: Phase 2 +1 more

4 metrics

Randomized participants 160 participants Phase 2 CALMA trial

Additional randomizations Up to 8 participants Before enrollment closure

Trial phase Phase 2 CALMA trial of IGC-AD1

Topline readout timing Q4 2026 Expected CALMA topline results

Previous Clinical trial Reports

5 past events · Latest: Jun 11 (Positive)

Same Type Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jun 11	Enrollment milestone	Positive	+0.5%	Reached planned enrollment target and allowed limited over-enrollment before topline analysis.
Jun 02	Clinical site addition	Positive	-1.7%	Added Mount Sinai site as trial participation progressed toward database lock and topline analysis.
Apr 28	Enrollment engagement	Positive	-2.1%	Caregiver podcast supported awareness and patient engagement while CALMA enrollment approached completion.
Apr 22	Clinical site addition	Positive	+10.2%	Added Kerwin Medical Center site to support final recruitment and data quality.
Apr 14	Enrollment progress	Positive	+4.4%	Reached final recruitment phase ahead of enrollment completion and topline results.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Tag-specific clinical-trial updates showed mixed reactions, with three aligned positive responses and two divergences.

Key Terms

randomized, double-blind, placebo-controlled, database lock, +1 more

5 terms

randomized medical

"CALMA is a randomized, double-blind, placebo-controlled Phase 2 trial"

Randomized means participants or units in a study are assigned to different groups by chance rather than by choice, like flipping a coin to decide who gets a new treatment and who gets a comparison. For investors, randomized designs matter because they reduce bias and make results more trustworthy, so outcomes from randomized studies carry more weight when assessing regulatory approval, commercial prospects, and the risk that trial results will change a company’s valuation.

double-blind medical

"CALMA is a randomized, double-blind, placebo-controlled Phase 2 trial"

A double-blind process means that neither the people conducting an activity nor the people involved know certain key details, such as who is receiving a treatment or a placebo. This approach helps prevent bias from influencing the results, making the outcome more trustworthy. For investors, it ensures that decisions or judgments are based on unbiased information rather than preconceived opinions or expectations.

placebo-controlled medical

"CALMA is a randomized, double-blind, placebo-controlled Phase 2 trial"

"Placebo-controlled" describes a testing method where one group receives the actual treatment or intervention, while another group receives a harmless, inactive version called a placebo. This approach helps determine whether the real treatment has genuine effects beyond psychological expectations. For investors, understanding this ensures confidence that reported benefits are real and not influenced by bias or false perceptions.

database lock medical

"before patient follow-up, database lock, unblinding, and topline analysis"

A database lock is the point in a clinical trial when the collected study data are finalized and no further changes or corrections are allowed, so analysts can run the official statistical tests. For investors this matters because it usually precedes public results or regulatory filings—think of it like sealing and signing off an exam before grading: once locked, the timing and content of the readout become clearer and uncertainty about last-minute data edits is reduced.

contract research organization technical

"OPIS Research, a full-service global contract research organization founded in Italy"

A contract research organization (CRO) is an outside company hired to run medical and scientific work for drug, device or biotech developers—like an experienced project manager and lab team that companies rent instead of building in-house. Investors care because CROs influence development speed, quality and cost: delays or successes in trials affect client spending, regulatory risk and ultimately revenues for both the sponsor and the CRO.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

POTOMAC, MD / ACCESS Newswire / August 11, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing treatments for Alzheimer's disease, today announced that it is strengthening its regulatory, biostatistical, artificial intelligence ("AI")-enabled data science, and strategic pharmaceutical development capabilities as IGC-AD1, the Company's lead Alzheimer's drug candidate, advances toward expected Phase 2 topline results in the fourth quarter of 2026.

CALMA has randomized 160 participants to date. IGC Pharma expects to close enrollment after up to additional participants, marking a key final enrollment milestone before patient follow-up, database lock, unblinding, and topline analysis. This final planned over-enrollment phase is intended to strengthen the dataset for end-of-treatment, secondary, and exploratory analyses.

The Company is strengthening these capabilities to support clinical data review, AI-assisted data quality activities, regulatory preparedness for potential engagement with the U.S. Food and Drug Administration ("FDA") and the European Medicines Agency ("EMA"), and strategic evaluation by potential pharmaceutical partners following completion of the Phase 2 CALMA trial. As part of this readiness effort, IGC Pharma has engaged OPIS Research, a full-service global contract research organization founded in Italy, to support EMA-related regulatory interactions.

"CALMA is moving through its final enrollment phase, and our focus is now on execution, data quality, and readiness for the next set of milestones," said Ram Mukunda, Chief Executive Officer of IGC Pharma. "With 160 participants randomized and up to eight additional randomizations expected before enrollment closure, we are preparing the CALMA dataset for rigorous scientific, regulatory, and strategic evaluation following completion of the Phase 2 trial. If supported by the CALMA results, we believe these activities could support a more efficient transition from clinical execution to data analysis, regulatory planning, and potential next-stage development."

IGC-AD1 is IGC Pharma's lead investigational therapeutic candidate for agitation associated with Alzheimer's dementia, a condition that creates significant burden for patients, caregivers, clinicians, and healthcare systems. CALMA is a randomized, double-blind, placebo-controlled Phase 2 trial designed to evaluate IGC-AD1 in this population.

As CALMA approaches enrollment closure and expected topline readout in the fourth quarter of 2026, IGC Pharma continues advancing both its Alzheimer's therapeutic pipeline and AI-enabled development capabilities in preparation for one of the Company's most significant clinical milestones to date.

About IGC Pharma, Inc. (dba IGC):

IGC Pharma, Inc. (NYSE American:IGC) is a clinical-stage biotechnology company leveraging AI to develop treatments for Alzheimer's disease and metabolic disorders. The Company's lead asset, IGC-AD1, is an investigational therapy currently being evaluated in the Phase 2 CALMA trial for agitation associated with Alzheimer's dementia. The Company's pipeline includes TGR-63, targeting amyloid plaques, and early-stage programs focused on neurodegeneration, tau proteins, and metabolic dysfunction. IGC Pharma integrates AI to support drug discovery, clinical trial optimization, and patient targeting.

Forward-Looking Statements:

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company's expected Phase 2 topline results, anticipated enrollment closure, patient follow-up, database lock, unblinding, topline analysis, regulatory preparedness, AI-enabled data science activities, potential engagement with regulatory authorities, potential strategic evaluation by pharmaceutical partners, and potential next-stage development of IGC-AD1. These statements are based on current expectations and involve risks and uncertainties that could cause actual results to differ materially, including risks related to the Company's ability to complete enrollment in its Phase 2 CALMA trial within anticipated timeframes, demonstrate safety and efficacy, maintain data quality, complete database and statistical analysis activities, achieve expected data readout timelines, obtain regulatory feedback or approvals, successfully implement regulatory, biostatistical, AI-enabled data science, and strategic development capabilities, attract or complete strategic evaluations or partnerships, and other factors discussed in the Company's filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 10-KT. The Company undertakes no obligation to update these statements except as required by law.

Investor Relations Contact
Andres Sanchez / Investor Relations
+1 301-983-0998 / +1 (202) 569-2566
info@igcpharma.com

SOURCE: IGC Pharma, Inc.

View the original press release on ACCESS Newswire

FAQ

What did IGC Pharma (IGC) announce about the Phase 2 CALMA Alzheimer's trial on August 11, 2026?

IGC Pharma announced that its Phase 2 CALMA trial for IGC-AD1 is nearing final enrollment, with 160 participants randomized. According to IGC Pharma, up to eight more participants may be added before closure, ahead of an expected topline data readout in the fourth quarter of 2026.

How many patients are enrolled in IGC Pharma’s CALMA Phase 2 trial for IGC-AD1 (IGC)?

CALMA has randomized 160 participants, with up to eight additional randomizations expected before enrollment closes. According to IGC Pharma, this final over-enrollment phase is intended to strengthen the dataset for end-of-treatment, secondary, and exploratory analyses in agitation associated with Alzheimer’s dementia.

When are topline results from IGC Pharma’s CALMA Phase 2 trial (NYSE American: IGC) expected?

Topline results from the Phase 2 CALMA trial are expected in the fourth quarter of 2026. According to IGC Pharma, this readout will follow patient follow-up, database lock, unblinding, and analysis, representing one of the company’s most significant upcoming clinical milestones.

What is IGC-AD1 in IGC Pharma’s pipeline and what does the CALMA study evaluate?

IGC-AD1 is IGC Pharma’s lead investigational therapy for agitation associated with Alzheimer’s dementia. According to IGC Pharma, the CALMA trial is a randomized, double-blind, placebo-controlled Phase 2 study designed to evaluate IGC-AD1 in this patient population using rigorous clinical endpoints.

How is IGC Pharma (IGC) using AI and data science in the CALMA Alzheimer’s trial?

IGC Pharma is leveraging AI-enabled data science to support data quality and clinical trial optimization. According to IGC Pharma, these capabilities assist with clinical data review, AI-assisted data quality activities, and strategic planning around regulatory readiness and potential partnering after completion of the Phase 2 CALMA trial.

What role does OPIS Research play in IGC Pharma’s regulatory preparations for CALMA (IGC)?

OPIS Research has been engaged to support EMA-related regulatory interactions for IGC Pharma. According to IGC Pharma, this full-service global contract research organization will contribute to the company’s broader effort to strengthen regulatory readiness ahead of potential discussions following completion of the Phase 2 CALMA trial.

What other Alzheimer’s drug candidates are in IGC Pharma’s (IGC) pipeline besides IGC-AD1?

Besides IGC-AD1, IGC Pharma’s pipeline includes TGR-63, which targets amyloid plaques, and early-stage programs in neurodegeneration, tau proteins, and metabolic dysfunction. According to IGC Pharma, these programs also integrate AI to support drug discovery, clinical trial optimization, and patient targeting across Alzheimer’s and metabolic disorders.